Tumor Biology

, Volume 37, Issue 2, pp 2721–2727 | Cite as

Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer

  • Qingjie Lv
  • Hanxue Sun
  • Chengcheng Cao
  • Bo Gao
  • Yafei Qi
Original Article

Abstract

Tumor necrosis factor receptor-associated protein 1 (TRAP1 or Hsp75) is a member of the mitochondrial heat shock proteins. TRAP1 expression is associated with drug and apoptosis resistance in various human cancers. This study assessed TRAP1 expression in tissue specimens of epithelial ovarian cancer (EOC) and its association with clinicopathological features and survival of EOC patients. Tissue samples from 356 patients were collected for immunohistochemical analysis of TRAP1 expression. TRAP1 levels in EOC tissues were significantly higher than that in noncancerous tissues. TRAP1 expression was associated with poor EOC differentiation, advanced pT stages, lymph node and distant metastasis, and advanced FIGO stages (p < 0.05). Kaplan-Meier survival analysis showed that TRAP1 expression was associated with poor prognosis of EOC patients and multivariate analysis revealed that TRAP1 expression (relative risk 6.720, CI 4.100–11.015, p < 0.001), tumor grade (p = 0.001), pathology stages (p = 0.001), and FIGO stage (p = 0.017) were all independent predictors of patients’ overall survival. These data demonstrate for the first time that increased TRAP1 expression was significantly associated with EOC stages and poor prognosis. Future studies are needed to confirm the role of TRAP1 as a prognostic tumor marker in EOC.

Keywords

TRAP1 Epithelial ovarian cancer Immunohistochemistry Biomarker Survival 

Notes

Acknowledgments

This work is supported in part by grants from Liaoning Science and Technology Plan Projects (#2013225021), Shenyang Special Funds of Technology Innovation Plan Projects (#F14-231-1-46), and Liaoning Pacesetter Engineering Projects (#2011921040).

Compliance with ethical standards

The described experiments comply with the current laws of China.

Conflicts of interest

None

References

  1. 1.
    Yan S, Deng Y, Qiang Y, et al. SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation. Tumor Biol. 2015;36:4633–42.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Landen Jr CN, Birrer MJ, Sood AK, et al. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995–1005.CrossRefPubMedGoogle Scholar
  4. 4.
    Landriscina M, Amoroso MR, Piscazzi A, Esposito F, et al. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol. 2010;117:177–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Hua G, Zhang Q, Fan Z, et al. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem. 2012;282:20553–60.CrossRefGoogle Scholar
  6. 6.
    Masuda Y, Shima G, Aiuchi T, Horie M, Hori K, Nakajo S, et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem. 2004;279:42503–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, Landriscina M, Esposito F, et al. Tumor necrosis factor-associated protein 1(TRAP-1) protects cells from oxidative stress and apoptosis. Stress. 2007;10:342–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Xiang F, Huang YS, Shi XH, Zhang Q, et al. Mitochondrial chaperone tumour necrosis factor receptor-associated protein1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. FEBS J. 2010;277:1929–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Tian X, Ma P, Sui C-G, et al. Suppression of TRAP1 expression induces inhibition of cell proliferation and tumor growth in human esophageal cancer cell. FEBS J. 2014;281(12):2805–19.CrossRefPubMedGoogle Scholar
  10. 10.
    Agorreta J, Hu J, Liu D, et al. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res. 2014;12(5):660–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ernst Justin T, Micheal L, Harmon Z, et al. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. Bioorg Med Chem Lett. 2014;24:204–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Maddalena F, Sisinni L, Lettini G, et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol. 2013;7:895–906.CrossRefPubMedGoogle Scholar
  13. 13.
    Altieri DC, Stein GS, Lian JB, Languino LR, Jordan SJ, Cushing-Haugen KL, et al. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:919–27.CrossRefGoogle Scholar
  14. 14.
    Lee C, Park H-K, Jeong H, et al. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. Am Chem Soc. 2015;137(13):4358–67.CrossRefGoogle Scholar
  15. 15.
    Qian H, Jing P, Weiping L, et al. Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. Int J Clin Exp Pathol. 2014;7(8):5057–70.Google Scholar
  16. 16.
    Guzzo G, Sciacovelli M, Bernardi P. Inhibition of succinate dehydrogenase by the mitochondrial chaperone TRAP1 has anti-oxidant and anti-apoptotic effects on tumor cells. Oncotarget. 2014;5(23):11897–908.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rasola A, Neckers L, Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol. 2014;24(8):455–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Condelli V, Piscazzi A, Sisinni L. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. Cancer Res. 2014;74(22):6693–704.CrossRefPubMedGoogle Scholar
  19. 19.
    Wertel I, Surówka J, Polak G, Barczyński B. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol. 2015;36(6):4811–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. Tumour Biol. 2015;36(6):4157–65.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ohkubo S, Kodama Y, Muraoka H. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther. 2015;14(1):14–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC, et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific HSP90 chaperone network. Cell. 2007;131:257–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Li S, Lv Q, Sun H, et al. Expression of TRAP1 predicts poor survival of malignant glioma patients. J Mol Neurosci. 2015;55(1):62–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Im C-N, Seo J-S, et al. Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1), leads to mitochondrial aberrations in mouse fibroblast NIH/3T3 cells. BMB Rep. 2014;47(5):280–5.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, et al. Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis. Gynecol Oncol. 2012;125:758–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Shen Y, Li DD, Wang LL, Deng R, et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 2008;4:1067–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, et al. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol Immunother. 2010;59:1313–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. Cancer Lett. 2009;279:39–46.CrossRefPubMedGoogle Scholar
  29. 29.
    Matassa DS, Agliarulo I, Amoroso MR, et al. TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumors. Mol Oncol. 2014;8(8):1482–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Amoroso MR, Matassa DS, Sisinni L, et al. TRAP1 revisited: novel localizations and functions of a ‘next-generation’ biomarker (review). Int J Oncol. 2014;45(3):969–77.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Qingjie Lv
    • 1
  • Hanxue Sun
    • 1
  • Chengcheng Cao
    • 1
  • Bo Gao
    • 1
  • Yafei Qi
    • 1
  1. 1.Department of PathologyShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations